{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:24:58Z","timestamp":1790749498699,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bulcan.2020.10.017","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T11:39:46Z","timestamp":1610105986000},"page":"725-729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["\u00c9ligibilit\u00e9 des patients aux cellules CAR-T\u00a0: avis d\u2019experts propos\u00e9 par la SFGM-TC"],"prefix":"10.1016","volume":"108","author":[{"given":"David","family":"Beauvais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Rabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2020.10.017_bib0080","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"10.1016\/j.bulcan.2020.10.017_bib0085","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/j.bulcan.2020.10.017_bib0090","first-page":"35","article-title":"CAR T-cells: A John von Neumann legacy?","volume":"66","author":"Quesnel","year":"2018","journal-title":"Curr Res Transl Med."},{"issue":"4","key":"10.1016\/j.bulcan.2020.10.017_bib0095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.bulcan.2020.10.017_bib0100","first-page":"93","article-title":"Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives","volume":"65","author":"Gauthier","year":"2017","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2020.10.017_bib0105","first-page":"43","article-title":"Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma","volume":"66","author":"Ghobadi","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2020.10.017_bib0110","first-page":"62","article-title":"Beginning the CAR T cell therapy revolution in the US and EU","volume":"66","author":"Grupp","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"19","key":"10.1016\/j.bulcan.2020.10.017_bib0115","doi-asserted-by":"crossref","first-page":"31368","DOI":"10.18632\/oncotarget.15572","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR\u201d","volume":"8","author":"Feldmann","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bulcan.2020.10.017_bib0120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.13889","article-title":"Chimeric Antigen Receptor (CAR) therapy for multiple myeloma","volume":"172","author":"Atanackovic","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bulcan.2020.10.017_bib0125","doi-asserted-by":"crossref","first-page":"e1308618","DOI":"10.1080\/2162402X.2017.1308618","article-title":"Novel anti-myeloma immunotherapies targeting the SLAM family of receptors","volume":"6","author":"Radhakrishnan","year":"2017","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.bulcan.2020.10.017_bib0130","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"3","key":"10.1016\/j.bulcan.2020.10.017_bib0135","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.bulcan.2020.10.017_bib0140","first-page":"79","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","volume":"67","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"S2","key":"10.1016\/j.bulcan.2020.10.017_bib0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hon.110_2630","article-title":"Real-world results on CD19\u00a0CAR T-cell for 60\u00a0French patients with relapsed\/refractory diffuse large B-Cell lymphoma included in a temporary authorization for use (ATU) Program","volume":"37","author":"Thieblemont","year":"2019","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2020.10.017_bib0075","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR-T Cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512030494X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512030494X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:34:19Z","timestamp":1757792059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512030494X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":15,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S000745512030494X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.10.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9ligibilit\u00e9 des patients aux cellules CAR-T\u00a0: avis d\u2019experts propos\u00e9 par la SFGM-TC","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}